Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Status:
Completed
Trial end date:
2020-05-20
Target enrollment:
Participant gender:
Summary
Study Objective:
1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic
COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus.
2. To test if early preemptive hydroxychloroquine therapy can prevent disease progression
in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and
symptom severity.
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota
Collaborators:
McGill University Health Centre/Research Institute of the McGill University Health Centre University of Alberta University of Manitoba